Accelerating Innovation at Leica Biosystems

Life Sciences Overview -$14.5B TOTAL REVENUE 2021E ●cytiva PALL Leica XIDT INTEGRATED DNA TECHNOLOGIES BECKMAN COULTER Life Sciences SCIEX Caldevron phenomenex MOLECULAR DEVICES MICROSYSTEMS By Geography HGM ROW W.EU By End-Market Clinical Ind. Applied Rese Aca All financial metrics reflect FY 2021E results from continuing operations; all pie chart percentages are % of 2021E revenues. • Increasing focus on genomic medicine • Vaccine, therapeutics & research in response to COVID-19 HGM investments in basic & applied research capacity Strong global brands with leading market positions DANAHER

View entire presentation